Triple independent lab testing with available documentation represents a level of transparency that may not be consistently found across all products in this category
"Emerging GLP-1 drugs are reshaping employers' 2026 priorities." About 90% of larger employers plan to continue covering GLP-1s
NDC 51662-1440-1 CYANOCOBALAMIN INJECTION, USP 10,000mcg/10mL (1,000mcg/mL) 10mL VIAL HF Acquisition Co LLC, DBA HealthFirst Mukilteo, WA 98275 Also supplied in the following manufacture supplied dosage forms Cyanocobalamin Injection, USP 1000 mcg/mL NDC 0517-0031-25 1 mL Fill in a 2 mL Vial Boxes of 25 NDC 0517-0032-25 10 mL Multiple Dose Vial Boxes of 25 NDC 0517-0130-01 30 mL Multiple Dose Vial Boxes of 1 Store at 20-25C (68-77F)
Price includes medication only, if prescribed
Hyperuricaemia occurs due to alterations in urate production or excretion
Importantly, no exploration of baseline differences between studies was included